Live tape
Top 8, mentions 7d2,137GOOGL453 mentions▲ +0.06NVDA345 mentions▲ +0.07META271 mentions▲ +0.05QQQ266 mentions▲ +0.09SPY256 mentions▲ +0.04AAPL193 mentions▲ +0.04MSFT178 mentions▲ +0.06TSLA175 mentions▲ +0.06

Equity · Healthcare

AGIO

Agios Pharmaceuticals, Inc. · NasdaqGS

$33 −2.94% 1D Finazon · prior-day close · Sep 18, 2026
Price · Chart
Our own end-of-day closes 63 sessions
$45 $25 22 Jun 18 Sep

The line runs $35 on 22 June through $33 on 18 September, on a scale from $25 to $45. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of AGIO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 63 sessions over that window: $35 on 22 June 2026 through $33 on 18 September 2026.

Market cap $2.0B
52-week range $23 – $45.46
Avg volume 59.2K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 20, 2026

AGIO insider trades

SEC Form 4 · last 90 days · newest reported trade 4 Aug 2026
Open-market buys 0
Open-market sells 2
Net sold $1.06M
Non-trade filings 2
Date Insider Type Shares Value
04 Aug 2026 Gheuens Sarah Chief Medical Officer Sell 30,000 $914K
01 Jul 2026 Gheuens Sarah Chief Medical Officer Sell 4,007 $151K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Jul 2026 Backstrom Jay T. Director Award 1,447
01 Jul 2026 Gheuens Sarah Chief Medical Officer Option exercise 8,375

AGIO reported financials

SEC EDGAR XBRL

AGIO reported revenue of $54.0M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$412.8M.

Figure Reported Period
Revenue $54.0M 31 Dec 2025 fiscal year
Net income −$412.8M 31 Dec 2025 fiscal year
Diluted EPS −$7.12 31 Dec 2025 fiscal year
Total assets $1.1B 30 Jun 2026 at period end
Total equity $1.0B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

AGIO earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-1.69 —
31 Mar 2026 Q1 2026 $-1.69 —
31 Dec 2025 FY 2025 $-7.12 —
30 Sep 2025 Q3 2025 $-1.78 —
30 Jun 2025 Q2 2025 $-1.93 —
31 Mar 2025 Q1 2025 $-1.55 —
31 Dec 2024 FY 2024 $11.64 —
30 Sep 2024 Q3 2024 $16.22 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

AGIO institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a AGIO position for the quarter ended 30 Jun 2026 — a combined $218.8M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
D. E. Shaw & Co. Held (±25%) +15.9% shares 3,107,005 $115.3M
Citadel Advisors Held (±25%) +18.2% shares 732,687 $27.2M
AQR Capital Management Added +1,779.5% shares 684,340 $25.4M
Two Sigma Investments Added +113.2% shares 536,380 $19.9M
Point72 Asset Management New position 506,344 $18.8M
Marshall Wace Trimmed −69.0% shares 138,800 $5.2M
Man Group Held (±25%) −13.7% shares 124,466 $4.6M
Tudor Investment Corp Held (±25%) +13.1% shares 65,779 $2.4M
Balyasny Asset Management Exited
Millennium Management Exited

Source: SEC EDGAR 13F filings

AGIO fails-to-deliver

SEC CNS data

On 17 Aug 2026, 94 shares of AGIO failed to deliver (about $3K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
17 Aug 2026 94 $3K <0.001%
14 Aug 2026 1 $33 <0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in AGIO

STOCK Act disclosures

The most recent congressional trade disclosed in AGIO is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 20 Aug 2026.

Date Member Type Amount
20 Aug 2026 filed 10 Sep 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K
03 Mar 2026 filed 07 Apr 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K

Source: U.S. House of Representatives financial disclosures